1-benzhydryl-3,5-dimethyl-1H-pyrazole | 77626-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzhydryl-3,5-dimethyl-1H-pyrazole
• 英文别名: 1-Benzhydryl-3,5-dimethyl-1H-pyrazol；1-(diphenylmethyl)-3,5-dimethyl-(1H)-pyrazole；1-benzhydryl-3,5-dimethylpyrazole
• CAS: 77626-33-6
• 化学式: C₁₈H₁₈N₂
• 分子量: 262.354
• InChiKey: PWAPVJPBKQOLFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-benzhydryl-3,5-dimethyl-1H-pyrazole 、 氨基钠 以92%的产率得到
  参考文献：
  名称：

  TERTOV B. A.; BOGACHEV YU. G., XIMIYA GETEROTSIKL. SOEDIN., 1981, HO 1, 119-120

  摘要：

  DOI：
• 作为产物：
  描述：

  (二苯基甲基)肼 、 乙酰丙酮 生成 1-benzhydryl-3,5-dimethyl-1H-pyrazole
  参考文献：
  名称：

  Darapsky, Journal fur praktische Chemie (Leipzig 1954), 1903, vol. <2> 67, p. 172

  摘要：

  DOI：

文献信息

• Study of the reactivity of α-acylenaminoketones. Synthesis of pyrazoles
  作者：Giuseppina Negri、Concetta Kascheres

  DOI：10.1002/jhet.5570380116

  日期：2001.1

  obtaining substituted pyrazoles and determining which of the carbonyls would preferentially be attacked by the nucleophile. The reactions of compounds 1–4 with hydrazine reagents led to the formation of the pyrazoles 5–7a-q. Small amounts of 4-methylamino-2-pentenones 10a-q, amides 11a-q and pyrazoles 12a-q were also obtained in these reactions. The unexpected formation of pyrazoles 15d,h,q was detected

  4-（甲基氨基）-3-戊烯-2-酮与重氮酮的反应以良好的收率得到了α-酰基亚氨基酮1-3。α-酰基亚氨基酮4的制备是通过用苯甲酰氯处理4-（叔丁基氨基）-3-戊烯-2-酮，然后与甲胺进行氨基转移反应来进行的。反应在五种不同的溶剂中进行，并进行了气相色谱/质谱分析，目的是获得取代的吡唑并确定哪些羰基化合物将优先受到亲核试剂的攻击。化合物1-4与肼试剂的反应导致形成吡唑5-7a-q。在这些反应中也获得了少量的4-甲基氨基-2-戊烯酮10a-q，酰胺11a-q和吡唑12a-q。当在α-酰基氨基酮4与肼试剂的反应中使用甲醇和N，N-二甲基甲酰胺作为溶剂时，检测到吡唑15d，h，q的意外形成。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004065393A1

  公开（公告）日：2004-08-05

  The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.

  该发明涉及式(I)的噻吩吡啶酮化合物：其中：R1为C1-6烷基，C2-6烯基或C3-6环烷基，可选地被C1-6烷基取代，上述每种基团可选地被一个或多个卤素原子取代；R2为C1-6烷基；R3为CO-G或SO2-G基团，其中G为含氮原子的5-或6-成员环，并且紧邻氮原子的第二杂原子为氧或硫，并且可选地被高达3个羟基和C1-4烷基基团中的一个或多个取代；Q为CR5R6，其中R5和R6如规范中定义；R4为含有0-4个独立选择的氮、氧和硫杂原子的5-至10-成员单环或双环芳香环系统，该环系统可按规范中描述的方式取代，并且其药学上可接受的盐和溶剂化合物。还描述了它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用，特别是在调节自身免疫疾病方面的应用。
• Novel compounds
  申请人：Cooper Edward Martin

  公开号：US20060052380A1

  公开（公告）日：2006-03-09

  The invention relates to thienopyridazinones of formula (I): wherein: R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl which is optionally substituted by C 1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R 2 is C 1-6 alkyl; R 3 is a group CO-G or SO 2 -G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C 1-4 alkyl; Q is CR 5 R 6 where R 5 and R 6 are as defined in the specification; and R 4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.

  本发明涉及式(I)的噻吩并吡嗪酮：其中：R1为C1-6烷基，C2-6烯基或C3-6环烷基，其可选地被C1-6烷基取代，上述每种取代基可选地被一个或多个卤素原子取代；R2为C1-6烷基；R3为CO-G或SO2-G基团，其中G为一个5-或6-成员环，其中包含一个氮原子和一个邻近氮原子的第二杂原子，所述环可选地被最多3个羟基和C1-4烷基中的一个或多个基团取代；Q为CR5R6，其中R5和R6如规范所定义；R4为一个5-到10-成员的单环或双环芳香环系统，其中包含0到4个独立选择的杂原子，包括氮、氧和硫，所述环系统可按规范中描述的方式取代，以及其药学上可接受的盐和溶剂化合物。还描述了其制备方法、含有它们的制药组合物以及它们在治疗中的应用，特别是在自身免疫性疾病的调节方面的应用。
• Compounds
  申请人：AstraZeneca AB

  公开号：US07064126B2

  公开（公告）日：2006-06-20

  The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO—G or SO2—G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C1-4 alkyl; Q is CR5R6 where R5 and R6 are as defined in the specification; and R4 is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.

  该发明涉及式（I）的噻唑吡啶酮，其中：R1是C1-6烷基，C2-6烯基或C3-6环烷基，可选地被C1-6烷基取代，上述每个基团可选地被一个或多个卤素原子取代；R2是C1-6烷基；R3是CO—G或SO2—G基团，其中G是含有氮原子和第二个杂原子，所述第二个杂原子选自氧和硫的5-或6-成员环，并可选地被多达3个羟基和C1-4烷基中的一种或多种基团取代；Q是CR5R6，其中R5和R6如规范中定义；R4是含有0到4个独立选自氮、氧和硫的杂原子的5-到10-成员单环或双环芳香环系，所述环系可按规范中描述的方式取代，以及其药学上可接受的盐和溶剂化合物。还描述了它们的制备过程、含有它们的制药组合物以及它们在治疗中的应用，特别是在自身免疫性疾病调节方面的应用。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1587809A1

  公开（公告）日：2005-10-26